Mavacamten Shows Promise in Heart Failure With Normal to Supranormal EF

(MedPage Today) -- There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial.
An established cardiac myosin inhibitor for hypertrophic cardiomyopathy...